Selective CCK‐A but not CCK‐B receptor antagonists inhibit HT‐29 cell proliferation: synergism with pharmacological levels of melatonin

González-Puga, Cristina; García-Navarro, Ana; Escames, Germaine; León, Josefa; López-Cantarero, Manuel; Ros, Eduardo; Acuña-Castroviejo, Darı́o

doi:10.1111/j.1600-079x.2005.00239.x

Cited by 29 publications

(28 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along the same lines, Gonzalez‐Puga et al. [175] reported that the indoleamine significantly inhibited cell proliferation and increased cancer cell death. Interestingly enough, melatonin acted synergistically with several CCK‐A antagonists, mainly devazepide, to further reduce HT‐29 cell growth.…”

Section: Responses Associated With Melatonin In Ibd and Colon Cancermentioning

confidence: 87%

New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin

Motilva

García‐Mauriño

Talero

et al. 2011

Journal of Pineal Research

104

View full text Add to dashboard Cite

: In intestinal bowel disease (IBD), immune‐mediated conditions exert their effects through various cells and proinflammatory mediators. Recent data support a participation of the endoplasmic reticulum stress and mitochondrial dysfunctions in IBD. Moreover, it is evident that chronic degenerative pathologies, including IBD, share comparable disease mechanisms with alteration in the autophagy mechanisms. Chronic inflammation in IBD exposes these patients to a number of signals known to have tumorigenic effects. This circuitry of inflammation and cancer modifies apoptosis and autophagy, and promotes cellular cycle progression, invasion, and angiogenesis. Melatonin has been shown as a specific antioxidant reducing oxidative damage in both lipid and aqueous cell environments. However, several studies provide further insight into the molecular mechanisms of melatonin action in the colon. In this line, recent data suggest that melatonin modulates autophagy and sirtuin activity. An anti‐autophagic property of melatonin has been demonstrated, and it could contribute to its anti‐oncogenic activity. Nevertheless, there is no information about whether antitumoral effects of melatonin on colon cancer are dependent on autophagy. Sirtuins have pleiotropic effects on cancer development, being reported both as facilitator and as suppressor of colon cancer development. Sirtuins and melatonin are connected through the circadian clock machinery, and melatonin seems able to correct the alterations in sirtuin activity associated with several pathological conditions. Autophagy and sirtuin activities are linked through 5′AMP‐activated protein kinase (AMPK) activation, which switches on autophagy and increases sirtuin. The effect of melatonin on AMPK and the impact of this effect on IBD and colon cancer remain an open question.

show abstract

Section: Responses Associated With Melatonin In Ibd and Colon Cancermentioning

confidence: 87%

New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin

Motilva

García‐Mauriño

Talero

et al. 2011

Journal of Pineal Research

104

View full text Add to dashboard Cite

show abstract

“…For example, in human HT‐29 CRC cells 1 mM melatonin for 24 hours increased flavone‐triggered apoptosis by incorporating oxidizable substrates into mitochondria. Also, melatonin enhanced chromatin condensation and DNA fragmentation, as well as 0.5‐2 mM inhibited uncontrolled cell proliferation and stimulated apoptosis in a dose‐dependent manner . In human SW480 and LoVo cells, 1 mM melatonin for 48 hours potentiated the apoptotic and antimetastatic effects, in combination with ursolic acid.…”

Section: Synergistic Actions Of Melatonin As Adjuvant Treatment In Crcmentioning

confidence: 93%

The emergence of melatonin in oncology: Focus on colorectal cancer

Gil‐Martín

Egea

Reíter

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Within the last few decades, melatonin has increasingly emerged in clinical oncology as a naturally occurring bioactive molecule with substantial anticancer properties and a pharmacological profile optimal for joining the currently available pharmacopeia. In addition, extensive experimental data shows that this chronobiotic agent exerts oncostatic effects throughout all stages of tumor growth, from initial cell transformation to mitigation of malignant progression and metastasis; additionally, melatonin alleviates the side effects and improves the welfare of radio/chemotherapy‐treated patients. Thus, the support of clinicians and oncologists for the use of melatonin in both the treatment and proactive prevention of cancer is gaining strength. Because of its epidemiological importance and symptomatic debut in advanced stages of difficult clinical management, colorectal cancer (CRC) is a preferential target for testing new therapies. In this regard, the development of effective forms of clinical intervention for the improvement of CRC outcome, specifically metastatic CRC, is urgent. At the same time, the need to reduce the costs of conventional anti‐CRC therapy results is also imperative. In light of this status quo, the therapeutic potential of melatonin, and the direct and indirect critical processes of CRC malignancy it modulates, have aroused much interest. To illuminate the imminent future on CRC research, we focused our attention on the molecular mechanisms underlying the multiple oncostatic actions displayed by melatonin in the onset and evolution of CRC and summarized epidemiological evidence, as well as in vitro, in vivo and clinical findings that support the broadly protective potential demonstrated by melatonin.

show abstract

“…The immunomodulatory effects of melatonin and its antineoplastic properties are currently under intensive investigation [89,90] . Experimental studies, carried out on animal models have demonstrated that pinealectomy enhances tumor growth and metastatic spread [91] .…”

Section: Melatonin As Single Antitumor Treatmentmentioning

confidence: 99%

Melatonin and Immunomodulation: Connections and Potential Clinical Applications

Giannoulia-Karantana

Vlachou²,

Polychronopoulou³

et al. 2006

Neuroimmunomodulation

View full text Add to dashboard Cite

Melatonin is the main hormone secreted by the pineal gland in the human brain. It has a strong impact on the sleep-wake cycle and is considered a general modulator of the human circadian rhythm. Apart from these well-established properties, melatonin possesses immunomodulatory, antioxidative and antiinflammatory properties. The potential ability of this hormone to act synergistically with several cytokines by enhancing their antitumoral activity and dramatically decreasing their adverse effects has placed melatonin among the new and promising agents in cancer immunotherapy. The use of the neurohormone alone or in combination with cytokines and traditional chemotherapeutic drugs is currently under vigorous investigation. Experimental and clinical trials have already depicted some of the immunomodulatory and antitumor effects of melatonin, delineating the need for further research in this field.

show abstract

Selective CCK‐A but not CCK‐B receptor antagonists inhibit HT‐29 cell proliferation: synergism with pharmacological levels of melatonin

Cited by 29 publications

References 49 publications

New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin

New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin

The emergence of melatonin in oncology: Focus on colorectal cancer

Melatonin and Immunomodulation: Connections and Potential Clinical Applications

Contact Info

Product

Resources

About